MDNA Medicenna Therapeutics Corp.

Medicenna Therapeutics Corp. is a clinical stage immuno-oncology company which engages in development and commercialization of selective versions of IL-2, IL-4 and IL-13 Superkines and Empowered Cytokines for the treatment of cancers. The company was founded by Fahar Merchant and Rosemina Merchant on February 2, 2015 and is headquartered in Toronto, Canada.

Note: This is not a U.S. company, but they cross-list their shares on a U.S. stock exchange - see the related symbol CT:MDNA.

$3.91
As of 02/26/2021     IEX book   CBOE book